Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

Phase 2CompletedNCT00810732

Pfizer27 enrolled

Overview

This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Chronic Kidney Disease

Interventions

OpenDRUG

Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)

NifedipineDRUG

Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)

PlaceboDRUG

Placebo for sitaxsentan, orally administered once daily (double blind arm)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy. Exclusion Criteria: * Required peritoneal dialysis or haemodialysis. * Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.

Locations (2)

Clinical Research Centre and Pharmacology Unit

Edinburgh, Scotland, United Kingdom

the University of Edinburgh, Western General Hospital, Department of Medical Sciences

Edinburgh, Scotland, United Kingdom

Outcomes

Primary Outcomes

Change From Baseline in Mean 24-Hour Urine Total Protein Level at Week 6

Mean urine total protein assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Baseline was derived from an average of Week 0 (pre-dose) 24-hour urine collections prior to each treatment period. Week 6 was derived from an average of Week 6 24-hour urine collections for each treatment period.

Time frame: Baseline, Week 6

Secondary Outcomes

Change From Baseline in Mean Systemic Arterial Blood Pressure (BP), Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 3 and 6

The 24-hour ambulatory BP monitoring was performed by using a BP cuff which was attached to the participant's arm, using the same arm throughout the study, with a small monitor that comfortably sits in the pocket of participant. Mean values over 24-hour measurements at each measurement period were calculated. The change in total 24-hour ambulatory monitoring of systemic arterial BP, SBP and DBP at Week 3 and 6 relative to baseline were reported. Baseline was as an average of the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period.

Time frame: Baseline, Week 3 and 6

Change From Baseline in Carotid-Femoral Pulse Wave Velocity (PWV) at Week 3 and 6

Carotid-femoral pulse wave velocity (PWV), a measure of arterial stiffness, is determined from the time taken for the arterial pulse to propagate from the carotid to the femoral artery. Baseline was defined as the pre-dose measurement for the measure collected at Week 0 of each treatment period. Week 3 and Week 6 was an average of measurement for the measure collected at Week 3 and 6 of each treatment period.

Time frame: Baseline, Week 3 and 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.